Weight loss drugs top the list for price negotiations - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Washington Wire
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Health/Employee Benefits News
Washington Wire RSS Get our newsletter
Order Prints
January 21, 2025 Washington Wire
Share
Share
Post
Email

Weight loss drugs top the list for price negotiations

Illustration of a scale with weight loss drugs and a tape measure on top. Weight loss drugs top the list for price negotiations.
Weight loss drugs top the list for price negotiations.
By Wire Reports

Weight loss drugs such as Ozempic, Rybelsis and Wygovy have skyrocketed in popularity for treatment of Type 2 diabetes and weight loss. But these drugs carry a steep price tag. On Friday, the Biden administration announced that the trio of weight loss drugs top the list of prescription drugs selected for Medicare price negotiations.

The list, which includes 15 drugs, up from 10 last year, is the first step in a negotiation process between Medicare and drugmakers that is expected to take place over the coming months. The new negotiated prices won’t take effect until 2027.

The list of drugs up for negotiation include:

The drugs selected to undergo negotiations are:

  • Ozempic; Rybelsus; Wegovy, for Type 2 diabetes and weight loss.
  • Trelegy Ellipta, an asthma treatment.
  • Xtandi, for prostate cancer.
  • Pomalyst, a chemotherapy drug.
  • Ibrance, a breast cancer drug.
  • Ofev, for idiopathic pulmonary fibrosis.
  • Linzess, a chronic constipation drug.
  • Calquence, a cancer drug.
  • Austedo; Austedo XR, for Huntington’s disease.
  • Breo Ellipta, a COPD drug.
  • Tradjenta, a diabetes drug.
  • Xifaxan, for diarrhea and irritable bowel syndrome.
  • Vraylar, an antipsychotic drug.
  • Janumet; Janumet XR, diabetes drugs.
  • Otezla, a psoriatic arthritis drug.

 

About 5.3 million people on Medicare used the drugs between Nov. 1, 2023, and Oct. 1, 2024, according to the Centers for Medicare and Medicaid Services.

Together, the 15 drugs selected accounted for $41 billion, or 14%, of total Medicare Part D spending. When combined with the first 10 drugs already negotiated by Medicare, they account for a third of all Part D spending, according to CMS. Medicare Part D covers prescription drugs that people take themselves, as opposed to those administered in a facility, such as chemotherapy.

"We have a chance to negotiate a better deal for the American people," outgoing Department of Health and Human Services Secretary Xavier Becerra said. "This is a big deal. Some folks have to cut their pills in half or skip a dose in their prescription so that they can make their prescription last longer."

Last year, Medicare reached agreements to lower prices on the 10 costliest drugs, including Eliquis, a blood thinner; Imbruvica, a blood cancer treatment; and NovoLog, a diabetes medication.

The new prices for those prescription medications are set to take effect in 2026.

© Entire contents copyright 2025 by InsuranceNewsNet.com Inc. All rights reserved. No part of this article may be reprinted without the expressed written consent from InsuranceNewsNet.com.

 

 

 

 

Wire Reports

Older

Economy performing better than expected, Morningstar says

Newer

Prudential study: Babies born today will likely need nearly $2M to retire

Advisor News

  • Survey: Most Americans still feel prosperous despite economic worries
  • SEC settlement would require Tai Lopez, two others, to pay $6.8 million
  • The Gen Z money paradox
  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
More Advisor News

Annuity News

  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • Boomers want retirement protection, but their actions don’t match their mindset
  • NAIC task force to address LTC riders
More Annuity News

Health/Employee Benefits News

  • States push short-term insurance as healthcare costs climb
  • Study Findings on Managed Care Are Outlined in Reports from Massachusetts General Hospital (A RUC Rescue of Primary Care?): Managed Care
  • Two May Work for You As One
  • AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
  • Court: California can mandate free abortions; insurers can charge for births
More Health/Employee Benefits News

Life Insurance News

  • AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
  • AM Best Takes Various Credit Rating Actions on Certain Subsidiaries of Auto-Owners Insurance Group
  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • AM Best Downgrades Credit Ratings of CICA Life Insurance Company of America
  • AM Best Upgrades Credit Ratings of CTBC Insurance Company Ltd
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.